Earnings call transcript Q2 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to Supernus Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session, instructions will follow at that time.

As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Peter Vozzo of ICR Westwicke, Investor Relations representative for Supernus Pharmaceuticals.

begin. may You

Peter Vozzo

market, Good us Steven. financial and you of thank conference release a Thank these announcing for afternoon Supernus joining results. the close the today Today, XXXX company Pharmaceuticals for issued call. press you, after everyone the second results quarter

at Officer, the the Dec. call is Today's with Executive being are Investor Chief of and ir.supernus.com. made Supernus' today the Khattar; website Financial via Relations call company's section On Chief available me, Jack Officer, Tim

course and performance. the current future statements make and call, certain forward-looking may During trends Supernus' of management the information. this statements reflect perspective existing regarding These events on future company's forward-looking

the SEC those projected of may Any performance including risks from and Risk such filings. differ of materially forward-looking involve these in uncertainties, Factors company's the Actual statements forward-looking section not results latest guarantees statements. future and in noted are those

be replay, August being For who additional those of of you, announcements may Since related XXXX. X, and the reference required listening may held the then, the have discussed. laws. to press to to company made declines is call these recorded obligation benefit this releases except the SEC. the filings securities Please company's Supernus any most the update statements, forward-looking and by topics applicable current as recent with on

the over turn to call now I'll Jack.

Jack Khattar

during us well brand to Thank execute flagship our you, quarter. Peter. of Good transition the continues exclusivity thanks as the we loss Trokendi to join discuss its for afternoon time everyone and year second on Supernus taking XR. with XXXX a

Trokendi deliver year far, Qelbree the compared net growth GOCOVRI, sales the This robust to quarter this same of represents to in XXXX. of year, XX% XR in with million exceeds achieving quarter period $XX growth and sales our continued second last decline $XX by the to million. products second the and In combined compared net growth

the significantly and the XXXX, net first $XX Supernus of Qelbree $XXX which million same from from period. in Trokendi for GOCOVRI, XR million sales exceeded the in Similarly, lost half generated

XX% Finally, excluding period first Trokendi XR, XXXX, half total last by with same revenues compared Supernus year. in the grew for the

specifics the in the beginning in strong Moving second ADHD on season of Qelbree's quarter, the market. weak the summer to more despite performance about

prescription ADHD the in IQVIA second essentially data, while compared X%, quarter all-time year, was the high market prescriptions first of quarterly this For in the grew of flat XXX,XXX reaching to quarter Qelbree's an prescriptions. by

growth XXX,XXX addition, resiliency sales increase showing the XX% represent grew second In Qelbree's net to in XXXX, the despite ADHD potential market. the Moreover, year. to quarter continued last brand seasonality the by quarter of second the compared a of in the the its compared XXX% quarter and prescriptions first quarterly

of we return several now metrics have As mid-August, the started approach the back-to-school season. signaling

have first demand shipments for setting in high demand For product. instance, the leading pharmacies. are typically significantly factory launch wholesalers from week are of pharmacy orders up indicator from compared a ramp new August June since starting Consequently, increased to product in of the the the good that to to satisfy and July, the

increase compared in of being the ago. XX% to compared and XX% of year average total an a to XX% resulted of price XX% the improvement more net, net to Moreover, Qelbree's to increase gross compared quarter quarter Qelbree second to XXXX. in average $XXX, Together per of one-third XXXX leading now this XXXX day an quarter a XXX several second dynamics, dose on continues milligram XQ an daily in capitalize prescription XXXX, including the compared prescriptions to in with to first per the increase

from up the prescribers of of from prescribers during expanded In Qelbree quarter, to XX,XXX XXXX. second addition, XX,XXX, the quarter base first its approximately

well as our behind the We salesforce with broader and back-to-school capacity expect continue as increased Qelbree's growth expansion reach season. to the

recent compared with a and article research about Drugs article are last research Price. reviewed Maxwell by Richard Doctors was we Price peer in very published the The that excited CNS authors, month Finally, the two routine of practice Viloxazine ADHD Atomoxetine Attention patients headline physicians. describes in an extended retrospective XX the independent clinical release for with by Disorder with a Deficit chart review Hyperactivity

pediatric and then treatment. further adult, out switched four of received to four days Patients, five Atomoxetine for up authorization. prior of over They to weeks weeks insurance required then were and washed Qelbree and

the Qelbree that were of prior they dose Approximately on maintained half patients or sub-optimal psychostimulants to receiving response. were with a stable on of a also Atomoxetine

or for of of the The trial during and scale were at study. Qelbree subsequent investigator adult four-week if at rating X rating administered the and end discontinued four-week trial. AEs symptom scale ADHD baseline, the earlier Atomoxetine the end At the

Briefly, the Qelbree showed the improvements the follows: Atomoxetine. less a article in than results on ADHD first, to the are P significant statistically value scales two are as X.XXXX highly of compared as with reported

over preferred Second, Qelbree Atomoxetine. XX% of patients

of stimulants XX% receiving stable Qelbree. off adjunctive patients Third, stimulant are taper chose on the once they to

the discontinued by response taking X% Atomoxetine positive Qelbree. versus discontinued reported finally, And Qelbree XX% to AEs. due week of XX% second Fourth,

note patients for adult In conclusion on improvement any "pediatric I experienced support release rapid inattention hyperactivity and greater and author's the Supernus optimal and with provide and article, summary, not Atomoxetine have extended this less published a ADHD or demonstrate funding impulsivity who the Viloxazine." in than that tolerability quote of research. as response did Please to

of Qelbree works has and for unique in differentiated shown great non-stimulant given sub a of and works both potential in clinical profile ADHD, We works, tolerability. the remain that scales confident fast, its

period million net to $XX This in XX% GOCOVRI, of in quarter now to XXXX. Switching represents the the increase increased second a healthy XXXX. sales product over same

to the the in annualized of net rate an with pleased million run be which sales. $XXX at brand, product $XXX approximately to million performance now is of continue We

$XX The are wholesalers same quarter. due and hit in XR, sales higher $XX compared rebates impacting same last million by were sales primarily all net product that Oxtellar million to gross Regarding was year. in to destocking hit, the period decline the

we from quarter sequentially down in XR, $XX $XX last year. were in expect first of market the generics For and million, Trokendi are There million on the in in quarter the million further the second down in sales from sales decline $XX quarterly the XR, net on three now brand. and XXXX product quarter second Trokendi of

in Given of now with Trokendi revised at the XR full $XX half the we the million year, have first midpoint approximately the for range slightly year guidance of performance the of XXXX.

on treatment-resistant Regarding product study in open the our pipeline, will on we and be an label with New we XX, City R&D overview Phase an you where York II an share hosting seizures. in patients with the XXXX, Day with of October adult emphasis clinical SPN-XXX pipeline will

adults depression, as mTORCX candidate in treatment-resistant the well is active orally which study new company's clinical a as first-in-class our SPN-XXX, activator, in program. from Phase DISCOVERY IIb with

development In addition, on and treatment paradigms, the will unmet leaders thought key share needs, company's perspectives clinical medical the their programs. current

collaboration of in with infusion continues this in team resubmission fourth to our hard for the work year. planned device towards of the quarter Our partners our apomorphine SPN-XXX, NDA

be position to strengthen looking in we for corporate CNS. to opportunities continue Finally, in further growth and strategic active development leadership our future

that, With call to turn will the Tim. now over I

Tim Dec

you, everyone. Jack. Good Thank afternoon

I quarter today. review today's second results, that press filed our XX-Q As XXXX release were please to and earlier refer

quarter last million sales million million quarter and XXXX revenue for the product in net royalty of $XXX.X revenue the second XXXX Total same to $XXX.X $X.X compared year. comprised $XXX.X was million. second of revenue of the quarter in of was Total

by product was decline offset The $XX in due to net a growth increase of products, $XX.X primarily sales sales GOCOVRI. million $XX.X million net sales and XR, product decrease net in million partially a of Trokendi product our Qelbree in

compared the Excluding quarter the for net to of XXXX increased Trokendi XR second same periods, in XX% sales year. last both product of total revenues period

as million last For combined were the for to year. R&D same million second of quarter SG&A $XXX.X the compared XXXX, expenses $XXX.X and period

While investment the and programs period second expenses increased in advancement R&D to pipeline. increased expenses SG&A year, quarter over with declined the XXXX million due our $X over same year clinical

operating million benefit year. tax Operating loss last of In to period GAAP tax of income same a million recorded earnings of as XXXX, XXXX second compared the income year. $XX.X $X.X same for $XX.X for was second the million period compared of the of million we last basis $XX.X expense to quarter the quarter an as on an for

loss million the diluted share the period same year. earnings in of diluted or GAAP $X.XX per GAAP compared second to XXXX of $XXX,XXX or share of of $X.XX last net per $X.X of net for quarter loss earnings

contingent million in $XX.X basis, of amortization assets, non-GAAP excludes a to adjusted intangible last same depreciation, compensation, and operating compared period which consideration, share-based the year. On $XX million was earnings

last ended year. comprised the royalty months Total turning of Now $XXX.X period were the to in was $XXX.X six-month million. numbers. to revenue June and million XXth, revenues Total product million of same million the revenue $XX.X compared sales net of $XXX.X for six XXXX

Trokendi of to decline XR, sales an the increase of to $XX million in in our decrease product sales offset growth net product and second through primarily quarter products, sales Similar $XX.X in were by GOCOVRI. results, million Qelbree net $XX.X due million the partially net product XXXX

of both same last in Excluding periods, to Trokendi the revenues increased net year. XR the sales total XXth, months June compared six ended period XX% XXXX product for

Combined same million R&D last $XXX as for compared ended XXth, million were and for period to expenses six SG&A XXXX months June the the $XXX.X year.

XXXX while pipeline. our our period million due same in over The investment expenses expenses to the second decreased, current SG&A quarter R&D $X.X increased

business. on clinical for As deliver Jack into an mentioned provide development be we October our more will which portfolio XXth, our R&D Day and our earlier, holding R&D will insight growth

earnings XXXX million last Operating million period $XX.X months as loss for same year. was of June to on a GAAP six basis compared operating for the ended $XX.X the

period income $XX.X tax the $X.X For same compared the XXXX, we six reported last million to benefit months million of benefit tax year. of as ended June income for an

six per net same XXth, year. XXXX were last June share $XX.X the period or the in compared for to per $XX.X share $X.XX or GAAP million months $X.XX earnings ended million diluted diluted

share-based which compensation, the $XX.X earnings million amortization consideration On again $XX.X million depreciation, excludes a operating same compared non-GAAP were to period adjusted last intangibles, year. in and basis, contingent

to the million cash, XXth, company and of December of securities As as million $XXX.X approximately marketable equivalents, XXXX, XXXX. compared cash had XXst, $XXX.X June in

repayment under notes. paid XXXX million to the operations. the total due principal convertible primarily convertible senior of Xst, was due of offset company decrease April by The partially $XXX.X generated XXXX, from notes, On amount cash its the

In remaining $X.X of of the addition million. interest outstanding to payment

Following convertible the the repayment, outstanding. no are longer XXXX notes

of the as credit XXXX, company line. XXth, borrowings repaid June against addition, fully In has the the

M&A sheet paying June company financial other of flexibility for of XXXX, different has two As potential instruments, these as a off and opportunities. balance significant XXth, result a value-creating strong and the

guidance. to Turning

full GAAP, the the total prior and year operating R&D, revenue, SG&A GAAP For earnings. expenses, for non combined financial reiterates company guidance XXXX, its and

from we such, range to million product sales and revenue. total expect comprised to As $XXX million revenues $XXX net royalty of

million $XX XXXX, range And GAAP range million to $XX operating $XXX million. range operating we non-GAAP from loss expect to full we of $XX $XXX combined SG&A full the R&D to and million earnings $XXX expect to the and from For million expenses year million. year to in finally,

prior issued refer identifies GAAP call Please that of non-GAAP. various reconciling ranges between items and the to this

With that, to the Q&A. I over operator will back the call now turn for

Operator

Thank you.

the We will Instructions] conduct question-and-answer [Operator now session.

comes question Andrew first Tsai of Jefferies. from Our

Andrew Tsai

all the thanks. afternoon. updates. Hi, Thanks questions. Good for Appreciate the

So, Qelbree, maybe, net did did also improved. seem on in sound the as the net if It gross to first QX. price question favorable

there So, the that question were QX? in happened fluctuations is, or any inventory destocking

then the are factory back-to-school it positive sounds you season. which in leading of like shipments ahead QX up a And ramping indicator. is said

So, should build we Thanks. inventory some in assume QX?

Jack Khattar

Andrew. Hi, Yes.

gear, Regarding the the get in kicking wholesalers with quarter, all remarks, lighter been rightfully back-to-school significant. orders my second I as would to did high reacting really bit in a and now along. light on as the has start said, inventory, Certainly the general to but into you mentioned in expect it pharmacies. nothing season, from It the we the Qelbree little

from prescriptions. the lead typically orders to obviously the and because increase and by very So, with increase pharmacies then indicator seeing react the pharmacies wholesalers increased They those from are their healthy us. orders a showing orders the react that to the that's increasing in already are orders

already cascading few a we're seeing with the first it's -- steps occurring there. really it's the So, and growth effect

weekly through then of in And also prescriptions, specifically on September we in time that moving see course, as on hopefully obviously will October. mid-August the goes

Andrew Tsai

XXXX, reach of and assume in that QX we can number, scripts, expect about, you're million than consensus third Qelbree's we, $XXX quarter trajectory assuming fair for of, QX needs financial the somewhere quarter comfortable to then to as speaking to rather closer is just TRX some and And be with sales third think to community, in it inflect Perfect. fourth to both what quarter. in

QX and thinking about QX a how Is in growth sales growth going beyond? it you. you in to basically are equally cadence? Thank the strong be So or quarter-to-quarter strong alone QX,

Jack Khattar

get quarter but is which so purely quarter third again quarter of we expect October a therefore back-to-school is as second half basis, the well Yes, sure, well on continue through quarter through and the mid-August the because back-to-school picking even is normally well the summertime the which which calendar July the I not third little soft, quarter in growth the will to expected a seasonality third So, really the funny, really the to calendar in it's in mean quarter. what fourth is purely normally on in up season, clearly, second falls the fourth the the in also season bleeds as in which prescriptions quarter. grow bit fourth and is also therefore third growth start and in will as clearly fourth again July it's the sales the a is happen the in is continue it's quarter. the June, soft and we to right? of into quarter top not quarter

Andrew Tsai

Perfect. much. very you Thank

Operator

moment next All Thank you. right. One question. for our

Koo comes question Stacy of next TD Cowen. from Our

Unidentified Analyst

and prospects the for expectation QX future among is line much adult This growth congratulations and the adult prescription questions. level adult you be on the for on the we quarter, ADHD what pediatric the growth Vish about please versus the there segment the So, Calgary you Stacey, breakdown and population? Could and clinician pediatric should taking population? the for Calgary is launch? as So thank for you. the for for think and adult less the our Hi. traction in in is of comment Thank seasonality group the what on so awareness

Jack Khattar

versus XX% saw in around adults X%-X%. second was we it pediatric, the segment in versus in adult in what by growth, the growth regarding approximately pediatric quarter, Yes, the

summertime, get only be still more of deeper year we're of picking went the launch much growth the get reach brand. in clearly, adult as trying brand. physician the so was the a So school, obviously, we're people up, about the still also, to the kids and into obviously, out adult of And adult within adult, into to is audience adopters

is segment. As the our the of probably go far so still around mix and rest as have it's in the long way the adult adult growth as XX% a our to XX%, as far in still business, is pediatric, we the

high school the of side, gear, with expect the Now to school back on to most to advantage in the would season back pediatric the you more pushing clearly now to season. be us take

balance on maybe side. the then later, out adult in it push And later we year, with the another

and execute So the and strategy audience, forth. different a on physician these awareness on we on basis, in what do adoption, strategies, depending obviously rate depending quarterly different rates the seasonality, the did you of growth different launch so

Unidentified Analyst

Perfect. prescriptions top-decile on mentioned the but you also to call some expanding new had lastly, last from so quarter prescribers, deepening And prescribers.

growing, deepening how progressing the and how you and So that base do prescriber expansion see moving forward? is

Jack Khattar

Clearly by for so field why in that's Salesforce fully expansion the I of we for the has the, mean, Yes, frame been the trained, completed. a Everybody that it design. in the time are, season. now. back-to-school has April-May was in timing been ready the did The expansion been everybody's has while field, we

the that frequency reach, So of will therefore, was is and XX of clearly the to the was things, of timing by the course, expand we to rest as do see the season year physicians. among out that back-to-school of to in increase all as clearly XX, reps two most of the designed expansion. and well That about expansion the design, the impact

And they lot is a top give numerous a best hyper-focused, of you of is who to see frequency to or course, patients, from into sales call. extremely It adopter, return on physician are is the on the This turn promotion. volume deciles, a that category which a sensitive an takes perspective, we important. so calls

Unidentified Analyst

you so Perfect. Thank much.

Operator

One you. for moment question. our Thank next

question next Our David Sandler. comes from Amsellem Piper of

David Amsellem

thanks. Hey,

got a just few. So,

be I'll about underlying First, essentially and way GOCOVRI? underlying I volumes missed trends know that I you're sales prescription this, a but if sorry different helpful. a alignment. but give in position would in or if talk Maybe you can ask for data, volume just don't to

to two pipeline your us you're latest of So stage is is an interesting question so you that's it are these an understand Then I number commercial guess about thought R&D at brings to And prioritize continuing or are assets going one. days number up there. And looking thinking additional have you BizDev? assets? process sort just are how you day, help

And lastly, you and that of other your then on next you thoughts you a for Oxtellar had won, year actually settled entry your Oxtellar, wanted generics. get to when couple on I XX why for cases was for

XX. Now, that up to pulls

there, is assets Just and the help you're thinking broader Thanks. us regarding it prioritizing? strategy tied to understand your

Jack Khattar

it's we starting I year, have be prescriptions. last like of it's Yes, what around in but GOCOVRI, this directly have And with the half growth the estimate, we versus because several to say Yes. X%, GOCOVRI buy first a on still with institutions, growth pharmacy, in on also the reason prescription us. first healthy from a specialty GOCOVRI, question we you, estimate year that accounts, so

So us. it's and little report prescriptions bit, a to don't they

So that's because is you're very accounts only it when stop product, really because the is fluctuation but a that who pharmacy this prescriptions are not why estimate on not to there's going on. point we IQVIA have specialty buying like sales. there prescriptions. important included. there necessarily, certainly they're And focus always we It's reading or are of reporting you buying because it no And sometimes a an quarter, quarter the

the these don't tend is and brand on sales sit on forth. like obviously, of especially a because they and pretty correlation inventory, institutions so to the unit between growth folks, basis So the high

surrogate product and of marker So behind I the the very, the would as the growth a sales and to look very product. good at health

can if commercial prioritize on question further the opportunities that continue we have to revenue that could and assets development, into Regarding the commercial business we cash flow the bring get company. second assets,

that have As our what next already a pipeline. is pipeline ahead potentially a level in be priority of could asset we launched

the in infusion clearly Phase advanced X. that, two most device. SPNXXX, one main point the pipeline, Our this are SPNXXX and the assets, infusion apomorphic is But right device, the behind at

X, if we X, from completed have these So, Phase Phase or in be assets other pipeline three ideal so we of completed that from us X, will can middle that assets Phase launch in even the find can years the for outside to two now. those

agnostic these We we're really perspective. operational on continue we either whether pretty are We're market criteria. Again, can from priority-wise, psychiatry neurology. focus an very flexible to So specific or address those comfortably.

question, on one, had paragraph the final most the And recent you the third situations the four XR Oxtellar regarding settlement. and

with say to settle table. get Looking at looking a that them, August, the that And the we legal attention with to Apotex really trial, we're us is so so in to which downside XXXX resources, on small very felt that this of have have off certain happened forth, at partial best July speak. that to risk early were situation so a or we optimum is the was year, downside, management happy fees, the for date, allocation would able and manage the very

half GOCOVRI. the to on date, on behind to the is which on it, important a more X, allocate than September Qelbree the were the a brands more and is if really clearly, palatable certainty, impact So bit a the Apotex's or clearly be a risk was even the That able that resources on of full situation, a off get strategy more XXXX, year little and year, hit take table will XXXX. which XXXX make adverse it

David Amsellem

That's Jack. helpful. Thanks,

Jack Khattar

Sure.

Operator

Annabel question [Operator Thank Our very of you much. from right. next All Samimy is Stifel. Instructions]

Unidentified Analyst

taking Thanks This questions. on Annabel. for is Jack Hi. for our

the a of non-stimulant thinking a stimulant And a in patient the a sense for when drug, you in now physicians So whether that what drug the on many like? with putting look profile reliable a do go-to patient gets is drug? that about new non-stimulant shift quarters on of there's have you're versus the put

Jack Khattar

experiencing to and Qelbree so and as speak with what we're Yes, I forth. can Qelbree directly clearly,

these stimulants. stimulants to the is that So happening, coming the lack business, are are around XX% of for being these Basically the that switches associated, shows coming stimulants. these from top are The Qelbree are products. the AEs patients and that actually other of switches Qelbree of bulk from The the reasons our patients where are research coming tolerability source coming to that or switching basically of switched are stimulants of the patients and XX% or from the are tolerability us actually stimulants. with franchise?

good second exist reason, people main stimulants the they stimulants mean, on forget different marketplace. but tried everybody to a even not on they've The response. stimulants if two been didn't have I they responds get that actually really

don't Third, tried so just have so specifically with weren't with forth. really them may experience they the they like to stimulants happy parents, too their give kids and they and

switches So from the the bulk of are coming stimulants.

the that, said we're that remaining patients patients. getting actually are XX%, XX% about of Now de we're getting the that or having business novo

and and we physicians of And I become So mentioned, really can encouraging that medication really is because the and these Qelbree, in physicians, the Qelbree that the lot treatment especially about either great remarkable now on go-to really that's hyperactivity of you mentioned because that recently, really, they've Qelbree. or very treatment where it's study it's before really inattention has are for who first-line other haven't a medication. with want patients physicians, for tried non-stimulant tolerability. they've to a and lot heard a Qelbree it, that tried anything are is works. of has a a as both physicians works with encouraging It's thinking first-line It experience which it's have and It I Qelbree summarize the works if based fast. had efficacy, out a that that for say they there us,

we've ADHD Yes, and for being the that's had has ADHD but market. we've this years in non-stimulant. decades market for many with up have split disappointed why been so other non-stimulants, the looking that's exactly now market of patients a XX% they And been what unfortunately, only

by works for as also fast. research is looking which on but Qelbree that been also And the that and delivering and we with a everything the Qelbree, mentioned that evident in today, non-stimulant reinforcing has we program. X works have saw that clearly, corroborating all Phase we the surveys have I on So been also

The the weeks and waiting weeks, to four when parents the have don't weeks, going a or product fast two waiting whether don't weeks, work not. not school five on onset or work. of forever six sometimes Strattera or after to weeks, even and atomoxetine action, starts waiting, week, Even wait may three and it's you know may

Qelbree is go that go-to I become, So for forced has to know the get after mentioned patients, and that even is beginning. with just Qelbree really short, they a that dissatisfied, exciting through through they lot it see the even edit physicians, it from to is a I long-winded answer, and for Qelbree XX research a article I step answer still if hasn't of with really atomoxetine, product are but they the four-week short to treatment the like done And an or research that, therefore, the patients. shows much response. incredible atomoxetine switch They the mentioned that the are these

in the marketplace. ofloxacin a head-to-head the to is forced of release prior physicians, existed actually data insurance and unlike study and but actually prove extended by they drug because conducted practice, is different or any clinical although unique Again, it's a this whole they were authorizations trial, these that they Qelbree ever other the and non-stimulant that two generated not

Unidentified Analyst

those then, that you stimulants, have tailwinds is? all from why previously a Got so patients I little that just that for necessarily weren't off converted been filling of bit, that it. but bit mentioned more Qelbree for shortages know And to explain as stimulant could you, a you've

Jack Khattar

and who The been a went the Yes. about couldn't has and patient you shortages, a pharmacy stimulant, think when it. to patient stimulant prescribed find that

medical what's for up from a the important that's treatment either perspective, made you. methylphenidate specific that a amphetamine important an doctor what's or It's and what have has the and first necessary decision the clinical and patient. or So is the what's really that point right made

that find that pretty probably back options reports amphetamine, has it, physician patient the if other much methylphenidate. they within can't XX the So

most up chewable So similar their likely different most a they've maybe made another release a formulation or release because tablet different stimulant whatever. to likely, a going prescribe clinically, is already versus or that immediate mind or or extended they're

the So necessarily it. first to them to patient we think is they when of why the can't Qelbree be that think option that physician that's going don't will the reports find

have try issues good dynamic the in to maybe from if may continues has is patient whom and necessarily too be that the another perspective, a it help, they a significant. that shortages rethink Qelbree. that that shortage for a good physician for They they really therapy non-stimulant Qelbree But say can't we make the if probably really felt with Now not and general. physician patient experience the are us appropriate, might may but would the

Unidentified Analyst

Thank That makes sense. you.

Jack Khattar

Sure.

Operator

closing comments. turn back to Jack Okay. for Thank the this you. I'm to like showing no further questions at Khattar time. I now would conference

Jack Khattar

you. would our that returning to strong is this afternoon, growth I priority. top to like our call In concluding Thank emphasize

Our XX% that $XX in XR. of products, significant of this first Trokendi half the year, in growth of far million exceeded Qelbree decline delivered the million in growth GOCOVRI, net and $XXX sales reaching by

on XXXX focused away be as XXXX to the stage making as continue as possible the from smooth products will and we continued for move set and transition We beyond. the growth legacy in

Thanks for call. R&D updating day to at to joining you look us seeing afternoon. October and XX this We on City our on New York you in forward our next

Operator

Thank for This you concludes conference participating. today's call.

You may now disconnect.

Supernus Pharmaceuticals (SUPN) 8 Aug 232023 Q2 Earnings call transcript